Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Roivant is debuting another "vant," dubbed Sinovant, whose mission is to "bring innovative medicines" to—you guessed it—China.
Arrakis CSO Jennifer Petter and Janssen's Clark Musto shared what it means to be trans in the biotech industry.
Chinese biotech Ascentage has raised another $150 million for its pipeline of drugs designed to induce programmed cell death in cancer.
SIGA Technologies tested its smallpox drug in 359 healthy volunteers to demonstrate safety and relied on animal data to show efficacy.
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.
U.K.-based CRO Clinigen has bought the rights to Novartis’ Proleukin (aldesleukin) outside the U.S. as it looks to boost sales.
Presage has an intratumoral microdosing platform designed to quickly evaluate how experimental solid tumor therapies perform in humans.
The mechanism by which PARP inhibitors in BRCA-mutated cancers work could make them applicable to many more cancer types.
Sangamo's SVP and Chief Technology Officer Michael Holmes is resigning to join an unnamed biotech startup.
GlaxoSmithKline is close to ending a six-decade drought in relapse-preventing therapies for Plasmodium vivax—one of the most common forms of malaria.